AGPAT2

Across TCGA pan-cancer cohorts, AGPAT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AGPAT2 data layer compared with 31 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher AGPAT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AGPAT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

LSCC, UCEC, and CCRCC are the cancer types where AGPAT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.824	1.000	.003	16	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.450	.018	12	view →
CCRCC	OS	Median	All	0.715	1.000	.028	11	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	6	view →
GBM	DFS	Quartile	All	0.621	0.802	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AGPAT2–LSCC (DFS)

Open the LSCC breakdown →